Leif Bergsagel, M.D., studies the molecular pathogenesis of multiple myeloma, which is a tumor of mature, isotype-switched plasma cells. Multiple myeloma is a treatable but incurable malignancy. In 1% of adults, a benign preclinical phase known as monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma.
Dr. Bergsagel's laboratory work focuses on understanding the molecular events that lead to the development of MGUS and its progression to multiple myeloma.